Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Selegiline for Parkinson's Disease

Selegiline

Selegiline belongs to a class of medications called MAO inhibitors. It is believed that this medication helps prevent the breakdown of dopamine in the brain. 

This medication is usually used at a later stage of Parkinson's disease and in combination with Sinemet®.

Side effects

Major side effects associated with selegiline include nausea, dizziness, abdominal pain and confusion.

Condition Spotlight

Patient Stories Parkinson’s Patient Spreads Awareness for the Disease with Push-Ups
New Technology Used to Treat Parkinson's Disease
New Technology Used to Treat Parkinson's Disease Play Video | 2:21
Stanford Hospital's Jaimie Henderson, MD, on Parkinson's Disease
Stanford Hospital's Jaimie Henderson, MD, on Parkinson's Disease Play Video | 3:22
Press Release From the Inside Out: Deep Brain Stimulation Designed to Control Parkinson's Disease

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Clinics for Selegiline